MMP9 and colorectal carcinoma: Reports suggest that dyscadherin/matrix metalloprotease 9 (MMP9) axis may be a viable therapeutic target for colorectal cancer (CRC) since it can accelerate the disease’s progression by altering TME through ECM remodeling [38].